Medtronic is excited by the updated European Hypertension Society (ESH) guidelines that highlight the role of renal denervation (RDN) as part of the hypertension care pathway. The guidelines were announced at the ESH 32nd Annual Meeting and simultaneously published in the Journal of Hypertension....
Work-Life Balance Challenges Take Toll as 48% of Surgeons Struggle with Burnout...
To enhance awareness around the importance of safety protocols, practices, and technologies to deliver optimum Patient and clinical outcomes as well as enable knowledge-sharing of best practices around this key area, BD (Becton, Dickinson, and Company) recently organized the ‘Pledge for Safety' - Clinical Leaders Forum....
Collaborative Decision-Making Process between Patients and Surgeons...
Kauvery Heart Institute, the center of excellence in comprehensive cardiac services at Kauvery Hospital - Radial Road, Kovilambakkam, proudly announces the launch of the latest AI-based Ultreon Coronary Imaging system. By acquiring this ground-breaking technology, Kauvery Hospital - Radial Road positions itself as the leader in Cardiac Sciences by being the first hospital in Tamil Nadu to acquire a state-of-the-art OCT system, empowering cardiologists with advanced capabilities for precise coron...
[Health System in New York City pilots the Studycast Integration Program using Us2.ai's complete echo AI tools for automating echo measurements. Core Sound Imaging's Studycast Integration Program has been designed to deliver a frictionless workflow for AI tools.]...
Building interdisciplinary, multisectoral partnerships to unite CVD action across borders...
System Allows Conversion to Reverse Shoulder Replacement Prosthesis...
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its Elecsys® beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys® Total-Tau CSF assays (tTau) have received U.S. Food and Drug Administration (FDA) 510(k) clearance. The Elecsys AD CSF Abeta42 and tTau assays (used as a tTau/Abeta42 ratio) measure two biomarkers of Alzheimer's pathology, beta-amyloid and tau proteins, in adults ages 55 and older being evaluated for the disease....
INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to expand the labeling on the INVOcell device and its indication for use to provide for a 5-day incubation period. The data supporting the expanded 5-day inc...
